The 2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

Adam J. Fein, Ph.D.
Drug Channels Institute

March 2020

Full report available at https://drugch.nl/pharmacy
LICENSE TERMS

This report is protected by copyright law. Unauthorized reproduction or distribution of this report or any portion of it may result in severe civil and criminal penalties and will be prosecuted to the maximum extent of the law. This report may be cited in commercial documents with full and appropriate attribution. Nothing in the license is intended to reduce, limit, or restrict any rights arising from fair use under copyright law or other applicable laws.

If you would like to quote from or otherwise cite the report, here is a suggested sample citation:


The complete End User License Agreement is available at: https://drugch.nl/2020EULA
ABOUT THE AUTHOR

Adam J. Fein, Ph.D., is the CEO of Drug Channels Institute (DCI), a leading management educator for and about the pharmaceutical industry. DCI is a subsidiary of Pembroke Consulting, Inc.

Dr. Fein is one of the country’s foremost experts on pharmaceutical economics and the drug distribution system. He has published hundreds of academic and industry articles, and is regularly quoted in such national publications as The Wall Street Journal, The New York Times, The Washington Post, Forbes, and many others.

His popular and influential Drug Channels website is the go-to source for definitive and comprehensive industry analysis, delivered with a witty edge. Drug Channels is the only place where you’ll find a serious discussion of PBMs, drug pricing, and pharmacy economics, all explained with humor and a healthy dose of pop culture.

Dr. Fein earned his doctoral degree from the Wharton School of Business at the University of Pennsylvania and his undergraduate degree from Brandeis University. He lives in Philadelphia with his wife, Paula, and their two children.

Contact information
Adam J. Fein, Ph.D.
Drug Channels Institute
1515 Market Street, Suite 960
Philadelphia, PA 19102
Phone: 215-523-5700
Website: www.DrugChannelsInstitute.com
Email: afein@drugchannels.net

Visit Dr. Fein’s Drug Channels website for the latest industry updates!

www.DrugChannels.net
ABOUT DRUG CHANNELS INSTITUTE

**Drug Channels Institute (DCI)**, a division of Pembroke Consulting, Inc., is a leading provider of specialized management education for and about the pharmaceutical industry.

In 2020, Drug Channels Institute will launch a new series of online training videos. They will combine Dr. Fein’s expertise and cutting-edge analysis—such as this *2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers*—into training videos that will offer your team a thorough grounding in crucial industry topics. These online tools will explain highly complex economic and business data and concepts so that you can:

- Make decisions that will best achieve your business goals
- Improve relationships with key accounts
- Understand your customers, channels, partners, and the economics of the U.S. pharmaceutical industry

Drug Channels Institute also hosts live webinars during which Dr. Fein discusses trends and policies that affect the pharmaceutical industry and its channels.

- [Click here to view our current and previous webinars.](#)
- [Click here to subscribe to Dr. Fein’s Drug Channels blog](#) and receive webinar announcements via email.

To learn more about how Drug Channels Institute can help your business, please contact:

Paula Fein, M.S.Ed.
V.P., Business Development
Drug Channels Institute
1515 Market Street, Suite 960
Philadelphia, PA 19102
Phone: 215-523-5700 x11
Website: [www.drugchannelsinstitute.com](http://www.drugchannelsinstitute.com)
Email: paula@drugchannelsinstitute.com
INTRODUCTION AND GUIDE TO THE 2020 REPORT

U.S. drug channels experienced an eventful 2019. The industry is confronting a diverse set of business, political, and legal challenges, some of which have persisted for years:

- Total prescription dispensing revenues of retail, mail, long-term care, and specialty pharmacies reached a record $446 billion in 2019. Specialty drugs accounted for 36% of these revenues—a new high for the industry.

- The largest insurers, PBMs, and specialty pharmacies have combined into vertically integrated organizations. They are poised to restructure U.S. drug channels by exerting greater control over patient access, sites of care, dispensing locations, and pricing.

- The specialty pharmacy industry continues to consolidate. UnitedHealth Group’s OptumRx business has acquired the two largest independent specialty pharmacies: Diplomat Pharmacy and Avella Specialty Pharmacy.

- Payers and PBMs are tightening their management of specialty drugs, which is pressuring independent specialty pharmacies, physician practices, and hospitals.

- Retail pharmacies experienced slowing growth, lower profits, and mounting competitive pressures. The U.S. pharmacy industry faces the prospect of a shakeout that would sharply reduce the number of pharmacy locations.

- List prices for brand-name drugs are growing at rates that are slower than historical norms. Deflation in generic drug prices continues, though the rate of change has steadied. Politicians continue to condemn increasing drug prices, though brand-name drugs’ net prices (after rebates and discounts) are declining.

- The gross-to-net bubble, which measures rebates and discounts paid by manufacturers, exceeded $170 billion in 2019. More people now face pharmacy benefit designs with coinsurance and deductibles. This development is raising awareness about the harm of basing patients’ out-of-pocket expenses on undiscounted list prices.

- Regulators, lawmakers, investors, and payers are publicly scrutinizing PBMs’ profit models. New disclosures about PBMs’ unexpectedly large profits in Managed Medicaid programs have triggered some states to reevaluate PBMs’ role and compensation.

- Outside investors have accelerated their pursuit of prescription dispensing. Amazon is still signaling that it wants to become a major participant in the pharmacy market, though its market share remains trivial. Venture capital firms are financing technology-enabled pharmacies that are attempting to alter traditional ways of doing business.
The federal government and multiple states are pursuing new policies aimed at introducing the commercial importation of drugs intended for foreign markets.

Regulatory efforts to remove the role of rebates in the drug channel system have failed. The prospects of federal legislative action regarding drug prices or the channel remain highly uncertain.

Understanding an Evolving Marketplace

The 2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers—our 11th edition—remains the most comprehensive, fact-based tool for understanding the entire U.S. drug pricing, reimbursement, and dispensing system. This unique resource is your ultimate guide to the complex web of interactions within U.S. prescription drug channels.

This definitive, nonpartisan resource includes the most current information about pharmacy dispensing channels, third-party payers, pharmacy benefit managers (PBMs), patients’ financial contributions, government regulations, and more. The report synthesizes a wealth of statistical data, research studies, financial information, and my own unique business consulting experience. It will aid pharmaceutical manufacturers, wholesalers, pharmacists, pharmacy owners, hospital executives, pharmacy buyers, benefit managers, managed care executives, policy analysts, investors, consultants, and many others.

Thousands of companies operate within the U.S. system, enabling more than 6.2 billion equivalent prescriptions to be dispensed and paid. The table below highlights the largest public companies that operate in the drug channel. Many of these firms are among the largest businesses on the Fortune 500 list.

### Major Public Companies Operating in U.S. Drug Channels

<table>
<thead>
<tr>
<th>Company</th>
<th>Stock Ticker</th>
<th>Primary U.S. Channel Role(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS Health</td>
<td>CVS</td>
<td>Chain drugstore/PBM/Mail &amp; specialty pharmacy/Insurer</td>
</tr>
<tr>
<td>Kroger</td>
<td>KR</td>
<td>Supermarket with pharmacy/Specialty pharmacy</td>
</tr>
<tr>
<td>Rite Aid Corporation</td>
<td>RAD</td>
<td>Chain drugstore/PBM</td>
</tr>
<tr>
<td>Walgreens Boots Alliance</td>
<td>WBA</td>
<td>Chain drugstore/Mail &amp; specialty pharmacy</td>
</tr>
<tr>
<td>Walmart Stores, Inc.</td>
<td>WMT</td>
<td>Mass merchant with pharmacy/Specialty pharmacy</td>
</tr>
<tr>
<td>AmerisourceBergen Corp.</td>
<td>ABC</td>
<td>Pharmaceutical wholesaler/Specialty pharmacy</td>
</tr>
<tr>
<td>Cardinal Health, Inc.</td>
<td>CAH</td>
<td>Pharmaceutical wholesaler</td>
</tr>
<tr>
<td>McKesson Corporation</td>
<td>MCK</td>
<td>Pharmaceutical wholesaler/Specialty pharmacy</td>
</tr>
<tr>
<td>Express Scripts, Inc. (Cigna)</td>
<td>CI</td>
<td>PBM/Mail &amp; specialty pharmacy/Insurer</td>
</tr>
<tr>
<td>Humana Pharmacy Solutions</td>
<td>HUM</td>
<td>PBM/Mail &amp; specialty pharmacy/Insurer</td>
</tr>
<tr>
<td>OptumRx (UnitedHealth Group)</td>
<td>UNH</td>
<td>PBM/Mail &amp; specialty pharmacy/Insurer</td>
</tr>
</tbody>
</table>

PBM = pharmacy benefit manager
Source: Drug Channels Institute research

These and other companies discussed in this report operate within a complex distribution, payment, and reimbursement system, illustrated on the next page.
The 2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers discusses the three key channel flows illustrated above:

- **Product movement**, which traces shipments from pharmaceutical manufacturers to the drug wholesalers that supply pharmacies. Retail, mail, long-term care, and specialty pharmacies mark the final step in which a prescription is dispensed to a patient.

- **Financial flows**, which transfer money from third-party payers to pharmacy benefit managers (PBMs), which in turn reimburse pharmacies. Funds flow to manufacturers via pharmacies, which purchase drugs from wholesalers. Funds flow from manufacturers to PBMS in the form of rebates. The PBMs share most of these rebate payments with plan sponsors, reducing plans’ net prescription costs. Manufacturers’ rebates to PBMs and other third-party payers do not flow through wholesale or retail channels.

- **Contractual relationships**, which govern the relationships between: 1) payers and PBMs; 2) PBMs and pharmacies; 3) pharmacies and wholesalers; 4) wholesalers and manufacturers; and 5) manufacturers and PBMs.

In Sections II and III of the report, we revisit this chart to associate each flow with the corresponding report chapters that explain and analyze it. To further explain these flows and their corresponding report chapters, the chart appears as Exhibit 64 (page 102).
What’s New in the 2020 Report

The 2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers retains the overall structure that we introduced in last year’s edition. However, some sections and chapters have been expanded or reorganized to better cover the latest industry developments. As always, we have updated all market and industry data with the most current information available, including our annual analyses of the market positions of the largest pharmacies, specialty pharmacies, and PBMs. The many significant changes and updates in this 2020 edition include:

• Chapter 2 incorporates significant revisions to certain prescription data based on IQVIA’s revised methodologies for measuring demand.

• We have expanded the Chapter 3 analysis of the specialty market, including new data and additional information about industry participants.

• In Chapter 6, the data on patient out-of-pocket expenses include new information on cost sharing and average out-of-pocket spending.

• Chapter 9 contains a new section with information on third-party payers, rebates, and benefit designs. We have also expanded our discussion of PBMs’ evolving profit sources.

• We have further streamlined the material on wholesalers in Chapter 10. Our companion Economic Report on Pharmaceutical Wholesalers and Specialty Distributors contains a detailed analysis of this sector.

• Chapter 11 includes significant new information based on our analyses of newly disclosed data on the following topics:
  o PBMs’ profit from spread pricing in Managed Medicaid programs
  o Direct and indirect remuneration (DIR) fees paid by pharmacies
  o Pharmacies’ profits from the 340B Drug Pricing Program

• Chapter 12, which was introduced last year and covers the industry outlook and emerging trends, has been expanded. Notable additions include new material on:
  o Consequences of vertical integration among insurers, PBMs, specialty pharmacies, and providers
  o Commercial importation of drugs intended for foreign markets
  o State Legislation of the Drug Channel
  o Specialty pharmacies’ role in cell and gene therapy channels

• Throughout the report, we have added new industry data sources, deepened our coverage of many topics, and added more trending information. There are 203 exhibits in the 2020 edition, compared with 180 in the 2019 edition.
Structure of the 2020 Report

This report analyzes the industry in 3 major sections, comprising 12 total chapters.

SECTION I: THE U.S. PHARMACY INDUSTRY

- **Chapter 1: Industry Overview** (page 9) defines the industry and its regulatory framework, describes the different products and prescriptions that a pharmacy dispenses, provides data on traditional and specialty prescription costs, delineates among different pharmacy industry participants, and quantifies differences among dispensing formats. This chapter includes our analysis of retail clinics and pharmacist-provided clinical services, including medication therapy management services.

- **Chapter 2: Pharmacy Industry Market Structure** (page 40) analyzes the industry’s prescription and revenue growth trends. It identifies the largest pharmacies based on prescription revenues. It then analyzes recent market share trends for each dispensing format and for the major national companies.

- **Chapter 3: Specialty Drugs and Specialty Pharmacies** (page 61) provides a comprehensive overview of the pharmacies dispensing specialty medications. It includes our exclusive analyses of national market share for pharmacy-dispensed specialty drugs and accreditation trends among pharmacies. It also provides a competitive analysis of the various organizations that compete to dispense specialty medications. The chapter reviews the channel strategies that pharmaceutical manufacturers use for specialty drugs, explains the role of service fees, and reviews the specialty hub services market.

SECTION II: THIRD-PARTY PAYMENT AND PHARMACY BENEFITS

- **Chapter 4: Payment and Spending for Prescription Drugs** (page 103) examines the primary payers for prescription drugs at retail, mail, long-term care, and specialty pharmacies. It analyzes recent changes in the payer mix and spending on traditional vs. specialty drugs. Chapter 4 also reviews the cash-pay prescription market and the use of discount card programs.

- **Chapter 5: Pharmacy Benefit Management** (page 122) identifies the services and roles of pharmacy benefit managers (PBMs). Chapter 5 also analyzes the structure of the PBM industry and reviews the business strategies of the largest PBMs. It describes the relationship between PBMs and the pharmacies that participate in a PBM’s network, reviews how pharmacy services administrative organizations (PSAOs) intermediate between retail pharmacies and PBMs, and explains how plan sponsors compensate PBMs for benefit management services.

- **Chapter 6: Consumer Copayments and Coinsurance** (page 149) analyzes the benefit designs and plan structures that determine patients’ out-of-pocket spending for the
major third-party payers: employer-sponsored health plans, Health Insurance Marketplace (HIM) plans, Medicare Part D, and Medicaid. We also explore manufacturers’ out-of-pocket payment support programs, explain the emergence and use of copay accumulators, and provide data on patient out-of-pocket expenses. We also explore how benefit design affect patients’ costs.

- **Chapter 7: Narrow Pharmacy Networks** (page 181) analyzes the structure, utilization, and economics of narrow network models. We explain the use and economics of narrow networks for pharmacies in commercial health plans and Medicare Part D. We review the use of mail and retail pharmacies as narrow network options for maintenance prescriptions. This chapter also evaluates the latest data on payer-defined networks for specialty drug dispensing in commercial health plans and for buy-and-bill channels.

### SECTION III: DRUG CHANNEL ECONOMICS AND OUTLOOK

- **Chapter 8: Prescription Reimbursement by Third-Party Payers** (page 207) explains the formulas and methodologies for computing a pharmacy’s revenue from brand-name, generic, and specialty prescriptions. This chapter compares traditional list price methods with acquisition-cost reimbursement approaches. We also review the economics of mail vs. retail pharmacies for payers and consumers.

- **Chapter 9: Drug Pricing, Rebates, and Payer Costs** (page 221) explores rebates in commercial health plans, Medicare Part D, and Medicaid. It explains how PBMs negotiate with manufacturers, analyzes trends in list and net drug prices, and describes the gross-to-net bubble phenomenon. The chapter includes a new section that explains how plan sponsors use rebates, the role of point-of-sale rebates, and controversies over rebates. The chapter concludes by illustrating how prescription reimbursement, formulary rebates, and consumer copayments affect a plan sponsor’s net costs for a typical traditional and specialty prescription.

- **Chapter 10: Relationships With Pharmaceutical Wholesalers** (page 252) explores pharmacies’ interactions with their primary wholesale suppliers of drugs. It explains wholesalers’ channel roles and services, identifies the largest wholesale suppliers, and analyzes how wholesalers affect pharmacies’ acquisition costs for drugs. We present our latest data on pharmacy group purchasing organizations and the generic sourcing relationships between wholesalers and large pharmacies.

- **Chapter 11: Pharmacy and Prescription Profitability** (page 265) unites the reimbursement and cost discussion from Chapter 8 and Chapter 10 by presenting the latest available data on pharmacy and prescription profitability. This chapter documents overall drugstore profitability, pharmacy margins for prescriptions from different dispensing formats, profit differences between brand and generic prescriptions, PBMs’ per-prescription profits from network and mail pharmacies, and a detailed review of
PBM’s spread pricing profits from Managed Medicaid programs. Chapter 11 also includes material on the direct and indirect remuneration (DIR) fee payments that pharmacies make to PBMs and health plans. Finally, we consider pharmacies’ role and profits in the 340B Drug Pricing Program.

- **Chapter 12: Outlook and Emerging Trends** (page 298) presents the outlook for net prescription drug spending, the future payer mix, and our updated projections for the pharmacy industry’s product mix and revenues in 2024. This chapter also considers future trends, including pharmacy-dispensed biosimilars, importation, state and federal legislation, cell and gene therapies, and such new entrants as Amazon and venture-backed startup pharmacies.

### How to Use the 2020 Report

*The chapters are self-contained and do not need to be read in order.* We include extensive internal clickable hyperlinks to help you navigate the entire document and customize it to your specific needs. After clicking a link, use the following shortcuts to return to your previous location in the document:

- **Windows:** ALT+Left Arrow
- **Mac:** Command+Left Arrow

There are more than 600 endnotes, most of which have hyperlinks to original source materials. The report also includes a list of the [Acronyms and Abbreviations](#) used within it. To search the entire PDF document for every occurrence of a word or phrase, use the following keyboard shortcuts:

- **Windows:** Shift+CTRL+F
- **Mac:** Shift+Command+F

As always, I welcome your feedback. Please contact me if you have any questions or comments about *The 2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers*.

Adam J. Fein
March 2020

P.S. [Click here for post-publication errata.](#)
CONTENTS

PREFACE: INDUSTRY TRENDS AND KEY REPORT THEMES .......................................................... 1

SECTION I: THE U.S. PHARMACY INDUSTRY ........................................................................... 8

Chapter 1: Industry Overview ...................................................................................................... 9

1.1. Pharmacy Fundamentals ........................................................................................................ 9

1.1.1. Defining the Practice of Pharmacy .................................................................................... 9

1.1.2. Pharmacies and the Drug Supply Chain Security Act ....................................................... 10

1.2. The Products That Pharmacies Dispense .............................................................................. 13

1.2.1. Brand vs. Generic Drugs .................................................................................................. 13

1.2.2. Traditional vs. Specialty Drugs .......................................................................................... 16

1.2.3. Top Therapy Classes and Average Prescription Costs .................................................... 19

1.3. Pharmacy Industry Participants .......................................................................................... 21

1.3.1. Pharmacy Dispensing Formats ......................................................................................... 21

1.3.2. Differences Among Outpatient Retail Dispensing Formats ............................................. 22

1.3.3. Pharmacist Salaries and Employment ............................................................................. 26

1.4. Healthcare and Clinical Services ......................................................................................... 29

1.4.1. Retail Clinics ..................................................................................................................... 30

1.4.2. Medication Therapy Management (MTM), Clinical Services, and Provider Status .......... 34

1.4.3. Immunization ................................................................................................................... 38

Chapter 2: Pharmacy Industry Market Structure ........................................................................ 40

2.1. Industry Trends .................................................................................................................... 40

2.1.1. Total and 30-Day Equivalent Prescriptions .................................................................... 40

2.1.2. Prescription Dispensing Revenues ................................................................................... 43

2.2. National Prescription Dispensing Market Share, by Company ........................................... 44

2.3. Trends by Dispensing Format .............................................................................................. 45

2.3.1. Revenues, Prescriptions, and Number of Pharmacies: Five-Year Trends ..................... 45

2.3.2. Market Changes in 2019 ................................................................................................ 47

2.3.3. National Retail Chains .................................................................................................... 48

2.3.4. Regional Drugstore Chains ............................................................................................ 54

2.3.5. Independent Pharmacies ............................................................................................... 55
Chapter 3: Specialty Drugs and Specialty Pharmacies .......................................................... 61
3.1. Specialty Pharmacies ................................................................................................. 61
3.1.1. Defining Specialty Pharmacy ............................................................................... 61
3.1.2. Clinical and Data Services .................................................................................. 62
3.1.3. Accreditation ....................................................................................................... 65
3.2. Specialty Pharmacy Market Structure ..................................................................... 67
3.2.1. Specialty Pharmacy Industry Market Size .......................................................... 67
3.2.2. Number of Accredited Specialty Pharmacies ....................................................... 69
3.2.3. National Market Share for Specialty Dispensing, by Company ......................... 71
3.2.4. Mergers and Acquisitions Among Specialty Pharmacies in 2019 ....................... 72
3.3. Trends by Specialty Dispensing Format .................................................................... 75
3.3.1. Overview ............................................................................................................ 75
3.3.2. Pharmacy Benefit Managers and Health Plans .................................................. 78
3.3.3. Independent Specialty Pharmacies ..................................................................... 81
3.3.4. Retail Community Pharmacies .......................................................................... 83
3.3.5. Hospitals and Health Systems ........................................................................... 85
3.3.6. Physician Practices and Other Providers ............................................................ 90
3.3.7. Pharmaceutical Wholesalers ............................................................................ 94
3.4. Manufacturer Channel Strategies for Specialty Drugs ............................................. 95
3.4.1. Manufacturer-Defined Dispensing Networks and REMS ................................ 95
3.4.2. Compensation for Clinical and Data Services .................................................... 97
3.4.3. Specialty Hub Services and Leading Providers ................................................... 100
SECTION II: THIRD-PARTY PAYMENT AND PHARMACY BENEFITS ............................ 102
Chapter 4: Payment and Spending for Prescription Drugs ............................................. 103
4.1. U.S. Healthcare Spending ......................................................................................... 103
4.1.1. Enrollment in Health Insurance ......................................................................... 103
4.1.2. Prescription Drugs and U.S. Healthcare Spending ............................................. 104
4.2. Payer and Spending Trends .................................................................................... 107
4.2.1. Payment for Outpatient Prescription Drugs ....................................................... 107
4.2.2. Trends in Drug Spending, by Payer .................................................................. 109
4.2.3. Trends in Drug Spending: Traditional vs. Specialty ........................................... 112
4.2.4. Deconstructing Changes in Cost vs. Utilization.................................................. 115
4.3. Cash-Pay Prescriptions and Discount Card Programs ............................................ 117

Chapter 5: Pharmacy Benefit Management .................................................................... 122
5.1. Overview of Pharmacy Benefit Management .......................................................... 122
5.1.1. Services for Plan Sponsors .................................................................................. 123
5.1.2. Relationships with Plan Sponsors ...................................................................... 123
5.1.3. Formulary Development and Management ........................................................... 126
5.1.4. Formulary Exclusions ......................................................................................... 127
5.1.5. Utilization Management ...................................................................................... 131
5.2. PBM Industry Structure .......................................................................................... 134
5.2.1. National Market Share, by PBM ......................................................................... 134
5.2.2. Business Trends for the Largest PBMs ............................................................... 135
5.2.3. Vertical Integration of Insurers, PBMs, Specialty Pharmacies, and Providers ........ 139
5.3. Relationships Between PBMs and Pharmacies ....................................................... 140
5.3.1. Pharmacy Participation in PBM Networks ......................................................... 140
5.3.2. PBM-Pharmacy Negotiations .......................................................................... 141
5.3.3. Pharmacy Services Administrative Organizations (PSAOs) ............................. 142
5.4. PBM Compensation by Plan Sponsors .................................................................... 145
5.4.1. Spread Pricing .................................................................................................... 147
5.4.2. Pass-Through Pricing ......................................................................................... 148

Chapter 6: Consumer Copayments and Coinsurance ...................................................... 149
6.1. Cost Sharing in Pharmacy Benefit Design ............................................................... 149
6.1.1. Employer-Sponsored Health Plans ................................................................... 150
6.1.2. Health Insurance Marketplace Plans ................................................................ 156
6.1.3. Medicare Part D ................................................................................................. 159
6.1.4. Medicaid ........................................................................................................... 165
6.2. Manufacturer Out-of-Pocket Payment Support ...................................................... 166
6.2.1. Copayment Offset Programs ............................................................................. 166
6.2.2. Copay Accumulator and Maximizer Programs ............................................... 170
6.2.3. Patient Assistance Programs ............................................................................ 172
6.3. Out-of-Pocket Expenses ................................................................. 173
6.3.1. Actual Patient Out-of-Pocket Spending on Prescriptions ............... 173
6.3.2. Consequences of Pharmacy Benefit Designs ................................ 177

Chapter 7: Narrow Pharmacy Networks .................................................. 181
7.1. Overview of Pharmacy Benefit Network Models ................................. 181
7.1.1. Network Options ........................................................................ 181
7.1.2. The Economics of Narrow Pharmacy Networks ............................... 183
7.1.3. Legal and Regulatory Restrictions on Network Design .................... 185
7.2. Retail Pharmacy Networks ................................................................ 186
7.2.1. Preferred Retail Networks in Medicare Part D ................................. 186
7.2.2. Narrow Retail Networks in Commercial and Other Plans ................ 194
7.2.3. Narrow Networks for Maintenance Prescriptions ............................ 196
7.3. Payer-Defined Specialty Dispensing Networks .................................... 200
7.3.1. Commercial Health Plans ............................................................ 200
7.3.2. Specialty Pharmacies’ Role in Buy-and-Bill Channels ..................... 202

SECTION III: DRUG CHANNEL ECONOMICS AND OUTLOOK ...................... 206
Chapter 8: Prescription Reimbursement by Third-Party Payers ................. 207
8.1. The Basics of Prescription Reimbursement ....................................... 207
8.1.1. Estimated Acquisition Cost (EAC) ............................................... 207
8.1.2. Dispensing Fees ......................................................................... 209
8.1.3. Service and Data Fees ............................................................... 210
8.2. Reimbursement for Brand-Name and Specialty Prescriptions .............. 210
8.2.1. Wholesale Acquisition Cost (WAC) and Average Wholesale Price (AWP) List Prices .......................................................... 210
8.2.2. AWP Discounts for Pharmacy Reimbursement ............................... 211
8.2.3. Why Mail Pharmacies Accept Lower Reimbursements ................. 214
8.3. Reimbursement for Generic Prescriptions ........................................ 215
8.3.1. Challenges for List-Price Benchmarks ......................................... 215
8.3.2. Maximum Allowable Cost (MAC) Limits and Generic Effective Rate (GER) ................................................................. 216
8.3.3. Regulations and Laws Regarding MAC Limits ............................... 217
8.3.4. Medicaid and Federal Upper Limits ............................................. 217
8.4. Acquisition Cost Reimbursement .................................................... 218
Chapter 9: Drug Pricing, Rebates, and Payer Costs ................................................................. 221

9.1. Rebates to Third-Party Payers ......................................................................................... 221
  9.1.1. How Commercial Payers Access Rebates ................................................................. 221
  9.1.2. Rebates and DIR in Medicare Part D ....................................................................... 226
  9.1.3. The Medicaid Drug Rebate Program ....................................................................... 229

9.2. Gross and Net Drug Pricing .......................................................................................... 233
  9.2.1. List vs. Net Drug Prices ......................................................................................... 233
  9.2.2. The Gross-to-Net Bubble ....................................................................................... 236

9.3. Issues with the Rebate System ....................................................................................... 239
  9.3.1. How Plan Sponsors Use Rebates ........................................................................... 239
  9.3.2. Point-of-Sale (POS) Rebates ................................................................................. 241
  9.3.3. Controversies Over Rebates ................................................................................. 243

9.4. How Prescription Reimbursement, Formulary Rebates, Consumer Copayments, and PBM Expenses Affect Plan Sponsor Costs ......................................................... 246

Chapter 10: Relationships With Pharmaceutical Wholesalers ........................................... 252

10.1. Overview of Wholesale Drug Channels ....................................................................... 252
  10.1.1. Industry Participants ............................................................................................. 252
  10.1.2. Product Distribution ............................................................................................. 253
  10.1.3. Financial Intermediation ....................................................................................... 254
  10.1.4. Other Services for Pharmacies, Providers, and Manufacturers ......................... 255
  10.1.5. Impact on Pharmacy Reimbursement ................................................................ 256

10.2. Determinants of Pharmacies’ Acquisition Costs .......................................................... 256
  10.2.1. Wholesaler Pricing of Brand-Name Drugs to Pharmacies ..................................... 256
  10.2.2. Pharmacy Group Purchasing Organizations ....................................................... 258
  10.2.3. Generic Sourcing Relationships Between Wholesalers and Large Pharmacies .... 261

Chapter 11: Pharmacy and Prescription Profitability ............................................................. 265

11.1. Overall Drugstore Gross Margins ................................................................................. 265
  11.1.1. Industry Averages .................................................................................................. 265
  11.1.2. Chain Drugstores ................................................................................................. 267

11.2. Pharmacy Per-Prescription Profits .............................................................................. 268
  11.2.1. Sources of Per-Prescription Profits .................................................................... 268
11.2.2. Average Per-Prescription Profits for Pharmacies ........................................ 269
11.2.3. PBM Per-Prescription Profits from Network and PBM-Owned Pharmacies .......... 272
11.2.4. The Impact of Brand-Name Inflation on Prescription Profits .......................... 276
11.2.5. Pharmacy Profits With Acquisition Cost-Based Reimbursement ....................... 278
11.3. Lifecycle Profitability for Generic Prescriptions .................................................. 280
11.4. Pharmacy DIR Fees in Medicare Part D Networks ............................................ 283
  11.4.1. Computation of Pharmacy DIR Fees .......................................................... 283
  11.4.2. Financial Impact of Pharmacy DIR Fees ...................................................... 284
  11.4.3. The Outlook for Pharmacy DIR Fees .......................................................... 287
11.5. Pharmacy Profits from the 340B Drug Pricing Program .................................... 288
  11.5.1. Overview of the 340B Program and Drug Prices ......................................... 288
  11.5.2. Companies Participating as 340B Contract Pharmacies ............................... 289
  11.5.3. Flow of Funds for a 340B Contract Pharmacy Network ................................ 293
  11.5.4. Pharmacy and Covered Entity Profits from 340B Prescriptions ...................... 294

Chapter 12: Outlook and Emerging Trends .............................................................. 298
12.1. Industry Outlook .................................................................................................. 298
  12.1.1. U.S. Net Spending on Outpatient Prescriptions from 2019 to 2024 ................. 298
  12.1.2. Payment for Outpatient Prescription Drugs in 2024 ..................................... 299
  12.1.3. Pharmacy Revenues from Traditional vs. Specialty Drugs in 2024 .................. 300
12.2. Drug Prices ......................................................................................................... 301
  12.2.1. The Outlook for Brand-Name Drug Prices .................................................... 301
  12.2.2. The Outlook for Generic Drug Prices ............................................................ 303
12.3. The Outlook for Biosimilars ................................................................................. 308
  12.3.1. Update on the Biosimilar Market ................................................................. 308
  12.3.2. Biosimilars Under the Pharmacy Benefit ....................................................... 310
12.4. Emerging Trends ................................................................................................. 312
  12.4.1. Consequences of Vertical Integration ........................................................... 312
  12.4.2. Importation From Foreign Markets ............................................................... 314
  12.4.3. State Legislation of the Drug Channel ............................................................ 315
  12.4.4. Specialty Pharmacies’ Role in Cell and Gene Therapy Channels .................... 317
  12.4.5. The Outlook for the 340B Program ............................................................... 319
12.5. New Entrants and Potential Pharmacy Market Disruption .............................................. 320
  12.5.1. Update on Amazon’s Potential Impact ........................................................................ 320
  12.5.2. Venture-Backed Online Pharmacies ........................................................................ 323

Acronyms and Abbreviations ........................................................................................................ 325

Endnotes ................................................................................................................................... 326
LIST OF EXHIBITS

Exhibit 1: Timeline of DSCSA Requirements for Pharmacies (Dispensers), 2013 to 2023............................... 10
Exhibit 2: Unbranded and Branded Generics, Share of U.S. Prescriptions, 2003 to 2024 ............................... 13
Exhibit 3: Top Traditional Therapy Categories, Generic Drugs as a Share of Prescriptions and Spending, 2018 ....... 15
Exhibit 4: Specialty Prescriptions, Number and Share of Total, 2014 to 2019 .................................................. 16
Exhibit 5: Top Specialty Therapy Categories, Generic Drugs as a Share of Prescriptions and Spending, 2018 ...... 18
Exhibit 6: Top Traditional Therapy Categories, Share of Spending and Average Net Prescription Costs, 2018 ...... 20
Exhibit 7: Top Specialty Therapy Categories, Share of Spending and Average Net Prescription Costs, 2018 ...... 20
Exhibit 8: Chain Drugstore Revenues, by Type of Merchandise, 2017 ............................................................. 23
Exhibit 9: Average Annual Number of Prescriptions per Pharmacy, by Retail Dispensing Format, 2019 ............ 24
Exhibit 10: Average Wait Time for Prescription Pickup, by Retail Dispensing Format, 2018 .............................. 24
Exhibit 11: Average Annual Prescription Revenue per Pharmacy Outlet, by Retail Dispensing Format, 2019 ...... 25
Exhibit 12: Top Four Reasons for Pharmacy Selection, by Dispensing Format ................................................... 25
Exhibit 14: Pharmacist Employment and Salary, by Employer, 2018 ................................................................. 27
Exhibit 15: Pharmacists, Change in Annual Average Salary, by Employer, 2014 to 2018 ................................. 28
Exhibit 16: Pharmacist Employment, by Industry and Dispensing Format, 2018 vs. 2028 ................................. 29
Exhibit 17: Insurance Coverage for Retail Clinics, 2010 to 2019 .................................................................... 30
Exhibit 18: Number of U.S. Retail Clinics, 2004 to 2020 ................................................................................. 31
Exhibit 19: Number of Retail Clinics, by Chain Location, 2020 ..................................................................... 32
Exhibit 20: Providers of Medication Therapy Management Services, Medicare Part D, 2019 ......................... 35
Exhibit 22: Adult Influenza Vaccination, by Place of Vaccination, 2012-13 vs. 2018-19 .................................... 38
Exhibit 23: Consumer Use of Immunization at Retail Pharmacies, by Dispensing Format, 2018 ...................... 39
Exhibit 24: Total U.S. Pharmacy Industry Prescription Revenues, Prescriptions, and Locations, by Dispensing Format, 2019 ................................................................. 40
Exhibit 25: Prescriptions, Annual Total and Growth, 2015 to 2019 ................................................................. 41
Exhibit 26: 30-Day Equivalent Prescriptions, Annual Total and Growth, 2015 to 2019 ................................. 41
Exhibit 27: 90-Day Prescriptions as a Percentage of Total Prescriptions, by Dispensing Format, 2019 ............ 42
Exhibit 28: Pharmacy Industry Prescription Revenues, Annual Total and Growth, 2015 to 2019 ................. 43
Exhibit 29: Largest 15 U.S. Pharmacies, by Total Prescription Revenues, 2019 ................................................. 44
Exhibit 30: Total Change in 30-Day Equivalent Prescriptions Dispensed and Prescription Revenues, by Pharmacy Type, 2013 vs. 2019 ........................................................................... 46
Exhibit 31: 30-Day Equivalent Prescriptions Dispensed per Location, by Dispensing Format, 2010 to 2019 ........ 46
Exhibit 32: Number of 30-Day Equivalent Prescriptions, by Dispensing Format, 2018 vs. 2019 .................... 47
Exhibit 33: Prescription Dispensing Revenues, by Dispensing Format, 2018 vs. 2019 ................................. 48
Exhibit 34: Year-Over-Year Change in Same-Store Prescription Count, by Chain, 2016 to 2019 ........................................... 49
Exhibit 35: Walgreens Boots Alliance, U.S. Store Count, 2016 to 2019 ................................................................. 51
Exhibit 36: Largest Regional Chain Drugstores, by Total Prescription Revenues, 2019 ......................................................... 54
Exhibit 37: Number of Independent Pharmacies, 2001 to 2019 ............................................................. 55
Exhibit 38: Pharmacy Franchise and Marketing Programs, 2019 ................................................................. 56
Exhibit 39: Share of Mail Pharmacy Dispensing Revenues, by Company, 2019 ......................................................... 60
Exhibit 40: Importance of Specialty Pharmacy Services to Patients, 2018 ................................................................. 63
Exhibit 41: Usage of Specialty Pharmacy Services by Patients, 2018 ................................................................. 64
Exhibit 42: Employer Perceptions of Specialty vs. Retail Pharmacies, 2017 ................................................................. 65
Exhibit 43: Specialty Prescription Dispensing Revenues, Annual Total and Growth, 2015 to 2019 ................................................................. 68
Exhibit 44: Specialty Drugs as a Percentage of Pharmacy Industry Prescription Revenues, 2013 to 2019 ........ 68
Exhibit 45: Specialty Drugs as a Percentage of Payers’ Pharmacy Benefit Spending, by PBM, 2013 vs. 2018 ...... 69
Exhibit 46: Number of Pharmacy Locations With Specialty Pharmacy Accreditation, by Organization, 2015 to 2019 ....................................................................................................................... 70
Exhibit 47: Locations With URAC Specialty Pharmacy Accreditation, 2008 to 2019 ................................................................. 71
Exhibit 48: Prescription Revenues and Market Share from Specialty Pharmaceuticals, by Company, 2019 ........ 72
Exhibit 49: Merger and Acquisition Transactions, Specialty Pharmacy and Infusion Services, 2014 to 2019 .... 73
Exhibit 50: Pharmacy Locations With Specialty Pharmacy Accreditation, by Corporate Ownership, 2019 ........ 75
Exhibit 51: Share of Pharmacy Locations With Specialty Pharmacy Accreditation, by Corporate Ownership, 2015 vs. 2019 ....................................................................................................................... 76
Exhibit 52: Specialty Drug Prescription Revenues, by Dispensing Format, 2019 ................................................................. 77
Exhibit 53: Specialty Drug Spending, by Dispensing Channel and Therapeutic Class, 2018 ................................................................. 78
Exhibit 54: Fastest-Growing Private Specialty Pharmacies, 2018 ................................................................................... 82
Exhibit 55: Retail Companies With Specialty Pharmacy Businesses, 2019 ................................................................. 85
Exhibit 56: Hospitals With a Specialty Pharmacy, by Number of Staffed Beds, 2016 vs. 2018 ................................................................. 86
Exhibit 57: Prescription Dispensing Revenues from Specialty Pharmacy, by Health System, 2019 ................................................................. 87
Exhibit 58: Hospital-Employed Physicians, 2012 to 2018 ................................................................................... 89
Exhibit 59: Health Systems’ Requirements for Employee Use of an In-House Pharmacy, 2019 ................................................................. 90
Exhibit 60: Percentage of Oncology Practices With In-Practice Oral Oncology Drug Dispensing, 2013 to 2018 .... 91
Exhibit 61: Patient-Administered Oncology Volume, by Dispensing Channel, 2019 ................................................................................... 92
Exhibit 62: Frequency of Manufacturer Contracting for Specialty Pharmacy Services, by Type of Service, 2017 to 2019 ....................................................................................................................... 98
Exhibit 63: Leading Specialty Hub Services Providers, 2019 ................................................................................... 101
Exhibit 64: Chapter Coverage of Flows in the U.S. Distribution and Reimbursement System ................................................................. 102
Exhibit 65: Health Insurance Enrollment, by Payer, 2008 vs. 2018 ................................................................................... 103
Exhibit 66: Share of U.S. National Health Expenditures, by Category, 2018 ................................................................................... 105
Exhibit 68: Growth in U.S. National Health Expenditures, by Major Spending Category, 2010 to 2018 .... 106
Exhibit 100: Percentage of Covered Workers with Pharmacy Benefit Deductibles, Employer-Sponsored Plans, 2007 to 2019 .......................................................... 156
Exhibit 101: Type of Cost Sharing for Prescription Drug Benefits, Silver Health Insurance Marketplace Plans, 2019 .......................................................... 157
Exhibit 102: Average Cost Sharing by Prescription Drug Tier, Silver Health Insurance Marketplace Plans, 2019 ................................. 158
Exhibit 103: Presence of Separate Prescription Drug Deductibles in Silver Plans on Health Insurance Marketplaces, 2014 to 2019 ........................................ 159
Exhibit 104: Medicare Part D Enrollment, by Type of Plan, 2010 to 2019 .............................................. 160
Exhibit 105: Average Number of Drugs Covered, Total vs. Specialty, Medicare Part D Plans, 2018 .................................................. 160
Exhibit 106: Standard Medicare Prescription Drug Benefit, 2019 .......................................................... 161
Exhibit 107: Distribution of Cost Sharing Formulas for Medicare Part D Plans, 2019 ........................................ 162
Exhibit 108: Median Copayments by Prescription Drug Tier, Medicare Part D PDPs, 2019 ................................. 163
Exhibit 109: Median Cost Sharing by Prescription Drug Tier, Medicare Advantage Plans, 2019 ................................. 163
Exhibit 110: Distribution of Coinsurance Rates for Specialty Drugs, Medicare Part D Plans, 2019 ....................... 164
Exhibit 111: Median Cost Sharing Amounts for 15 Largest Medicare Part D Plans, 2019 ........................................ 164
Exhibit 112: Prevalence of Copayment Offset Programs for Specialty Drugs, 2016 vs. 2020 ................................. 166
Exhibit 113: Maximum Annual Benefit for Copayment Offset Program, by Specialty Therapy Class, 2020 ............. 167
Exhibit 114: Manufacturer Spending on Copay Offset Programs, 2010 to 2019 .............................................. 168
Exhibit 115: Employer Views on Specialty Copayment Assistance Programs, 2018 .............................................. 169
Exhibit 116: Large Employers’ Tactics for Managing Copay Offset Programs, 2019 .............................................. 169
Exhibit 117: Pharmaceutical Manufacturer Charitable Foundations, by Total Giving, 2017 .................................. 173
Exhibit 118: Consumers’ Out-of-Pocket Spending Share of Outpatient Prescription Drug Expenditures, 1968 to 2018 .............................................. 174
Exhibit 119: Consumers’ Per Capita Out-of-Pocket Spending on Outpatient Prescription Drugs, 2010 to 2018 ................................. 174
Exhibit 120: Average Per-Prescription Patient Out-of-Pocket Costs, by Type of Prescription, 2014 to 2018 ................................. 175
Exhibit 121: Distribution of Annual Patient Out-of-Pocket Spending, by Type of Health Plan, 2018 ......................... 176
Exhibit 122: Distribution of Out-of-Pocket Spending, by Type of Payment, 2004 vs. 2017 ................................. 177
Exhibit 123: New Patient Abandonment, by Patient Out-of-Pocket Cost and Payer, 2018 ................................. 179
Exhibit 124: Consumer Understanding of Health Insurance Terms, 2016 vs. 2019 .............................................. 179
Exhibit 125: CVS Health, Quarterly Retail Prescription Revenues, 2014 to 2019 .............................................. 180
Exhibit 126: Summary of Pharmacy Benefit Network Design Options .......................................................... 182
Exhibit 127: Average Distance to Nearest Pharmacy, by Core Based Statistical Area (CBSA) Status, 2017 ................................. 183
Exhibit 128: Medicare Part D PDPs With Preferred Pharmacy Networks, 2011 to 2020 ................................. 187
Exhibit 129: Medicare Part D Beneficiary Access, Preferred Pharmacies vs. All Network Pharmacies, 2017 ................................. 188
Exhibit 130: Participation as a Preferred Cost Sharing Pharmacy in Selected Medicare Part D PDPs, by Retail Chain, 2019 .......................................................... 190
Exhibit 131: Enrollment in Medicare Part D PDPs with Preferred Cost Sharing Networks, by Pharmacy Chain, 2017 to 2020 .......................................................... 192
Exhibit 132: Participation as Preferred Cost Sharing Pharmacy in Selected Medicare Part D PDPs, by PSAO, 2020 193
The 2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

Exhibit 133: Share of Large Employers with Narrow Retail Pharmacy Network, 2013 to 2019 ................................................. 195
Exhibit 134: Mandatory Mail Pharmacy Utilization for Maintenance Medications, Employer-Sponsored Plans, 2013 to 2018 ................................................................. 197
Exhibit 135: TRICARE, Net Spending on Outpatient Prescriptions, by Dispensing Outlet, 2012 to 2018 .................. 198
Exhibit 137: Payers’ Perceived Lowest-Cost Site of Care for Specialty Dispensing, 2018 ......................... 200
Exhibit 138: Share of Large Employers with Restricted Specialty Pharmacy Network, by Network Size, 2011 to 2019 ........................................................................ 201
Exhibit 139: Oral Oncology Agents, by Dispensing Channel, 2009 vs. 2019 ................................................. 202
Exhibit 140: Drug Sourcing for In-Practice Administration, by Practice Type and Source, 2018 .................. 204
Exhibit 141: Drug Sourcing for In-Practice Administration, Physician Offices, 2010 vs. 2018 .................. 205
Exhibit 142: Payer Methodologies for Computing a Pharmacy’s Estimated Acquisition Cost .................. 209
Exhibit 143: AWP Reimbursement and Copayments for Brand-Name Prescriptions, by Dispensing Format, 2018 212
Exhibit 144: AWP Reimbursement Difference, Retail vs. Mail Pharmacies, 2008 to 2018 ......................... 213
Exhibit 146: AWP Reimbursement and Copayments for Generic Prescriptions, by Dispensing Format, 2018 .... 215
Exhibit 147: Pharmacy Reimbursement Methodology and Dispensing Fee, Largest Fee-for-Service State Medicaid Programs, 2019 ................................................................. 220
Exhibit 148: Percentage of Employers Receiving No Rebates for Brand and Specialty Drugs, 2014 vs. 2019 ........ 222
Exhibit 149: PBM Rebate Arrangements for Traditional Medications in Employer-Sponsored Plans, by Employer Size, 2014 vs. 2019 ................................................................. 222
Exhibit 150: PBM Rebate Arrangements for Specialty Medications in Employer-Sponsored Plans, by Employer Size, 2014 vs. 2018 ........................................................................ 223
Exhibit 151: CVS Health, Brand-Name Rebates Per Commercial Life and Share Retained by PBM, 2011 to 2019... 225
Exhibit 152: Total PBM-Negotiated Rebates and Share Retained, Diabetes Drugs in Nevada, 2017 to 2018 .......... 226
Exhibit 153: Medicare Part D, Direct and Indirect Remuneration (DIR) as a Percentage of Total Gross Drug Spending, Medicare Part D, 2011 to 2019 ................................................................. 227
Exhibit 154: Medicare Part D, Direct and Indirect Remuneration (DIR), by Source, 2013 vs. 2019 .................. 228
Exhibit 155: Medicaid Program, Gross Spending and Prescriptions, Fee-For-Service vs. Managed Care, 2018 .... 232
Exhibit 156: Medicaid, Gross vs. Net Spending on Outpatient Drugs, 2015 to 2018 ................................................. 233
Exhibit 158: Change in List vs. Net Price, by Manufacturer, 2018 ................................................................. 235
Exhibit 159: Total Value of Pharmaceutical Manufacturers’ Gross-to-Net Reductions for Brand-Name Drugs, 2014 to 2019 ................................................................. 237
Exhibit 160: Total Value of Pharmaceutical Manufacturers’ Gross-to-Net Reductions for Brand-Name Drugs, by Source, 2019 ........................................................................ 239
Exhibit 161: Employers’ Use of Formulary Rebates, 2017 ........................................................................ 241
Exhibit 162: Large Employers’ Point-of-Sale Rebate Programs, 2019 to 2022 ................................................................. 242
Exhibit 194: Source of Payment for Outpatient Prescription Drug Expenditures, 2023 ........................................ 299
Exhibit 195: Total Brand Revenues Lost to Generic Launches, by Product Type, 2014 to 2024 ................................. 300
Exhibit 196: Pharmacy Industry Prescription Revenues, Traditional vs. Specialty Drugs, 2014 to 2024 ..................... 301
Exhibit 197: Median Generic Price Relative to Brand Price Before Generic Entry, by Number of Manufacturers... 304
Exhibit 198: Gleevec, Average Pharmacy Acquisition Cost, Brand vs. Generic, 2016 to 2020 ................................. 305
Exhibit 199: Average Year-Over-Year Change in Pricing of Mature Generic Drugs, Oral vs. Injectable, 2015 to 2020 ........................................................................................................ 306
Exhibit 200: Generic Drug Approvals, FDA, 2014 to 2019 ......................................................................................... 308
Exhibit 201: FDA-Approved Biosimilars, Patient-Administered Drugs, 2016 to 2020 .............................................. 311
Exhibit 202: Consumer Interest in Obtaining Prescriptions from Amazon, by Usual Dispensing Format, 2018 ...... 322
Exhibit 203: Venture Capital-Backed Online Pharmacies, 2020 .............................................................................. 324